Comprehensive Intelligence Report: BLU-808, a Novel Wild-Type KIT Inhibitor for Mast Cell-Mediated Diseases

Executive Summary

BLU-808 is an investigational, oral, once-daily small molecule being developed by Blueprint Medicines, a company recently acquired by Sanofi. It is engineered as a highly potent and selective inhibitor of wild-type KIT, a receptor tyrosine kinase that serves as the master regulator of mast cell survival and activation. This positions BLU-808 as a potential first-in-class oral therapy for a broad range of mast cell-mediated inflammatory and allergic diseases, with an initial focus on chronic urticaria and allergic rhinoconjunctivitis.

The therapeutic rationale for BLU-808 is to address the root cause of these conditions by modulating mast cell activity, a more fundamental approach than targeting downstream mediators or activation pathways. This strategy represents a significant expansion for Blueprint Medicines, leveraging its deep expertise in KIT biology—honed through the development of the mutant KIT inhibitor avapritinib for oncology—into the much larger immunology market.

Preclinical data demonstrate a best-in-class profile, characterized by sub-nanomolar potency against wild-type KIT and exceptional selectivity, thereby avoiding off-target kinases associated with the toxicities of earlier-generation inhibitors. This profile translated into a completed Phase 1 study in healthy volunteers that established an exceptionally wide therapeutic window. The trial showed that BLU-808 was remarkably well-tolerated, with no adverse events greater than Grade 1, and demonstrated robust, dose-dependent target engagement, evidenced by serum tryptase reductions exceeding 80%. The pharmacokinetics support a convenient once-daily oral dosing regimen.

Competitively, BLU-808's oral administration and fundamental mechanism of action position it favorably against both established injectable biologics like omalizumab and emerging oral therapies such as Bruton's Tyrosine Kinase (BTK) inhibitors. By targeting the core driver of mast cell function, BLU-808 may offer broader efficacy across different disease endotypes.

The strategic importance and perceived blockbuster potential of BLU-808 were strongly validated by Sanofi's acquisition of Blueprint Medicines for approximately $9.1 billion upfront. The deal structure notably includes a specific Contingent Value Right (CVR) tied to BLU-808's future clinical and regulatory milestones, which could add approximately $400 million to the total deal value. This CVR serves as a powerful de-risking event and a testament to the asset's perceived value.

BLU-808 is currently advancing into multiple Phase 2 proof-of-concept studies. Success in these trials would solidify its standing as a leading next-generation oral therapy for a wide spectrum of allergic and inflammatory conditions, representing a significant commercial opportunity.

Introduction: A New Paradigm in Mast Cell Modulation

BLU-808 is an investigational, orally administered small molecule designed as a highly potent and selective inhibitor of wild-type KIT (also known as c-Kit), a receptor tyrosine kinase.[1] The drug was discovered and is being developed by Blueprint Medicines, a company with deep, established expertise in the biology of the KIT pathway, most notably through its successful development and commercialization of avapritinib (AYVAKIT), an inhibitor of

mutant forms of KIT for the treatment of rare cancers like systemic mastocytosis (SM) and gastrointestinal stromal tumors (GIST).[1]

The development of BLU-808 represents a deliberate and insightful strategic expansion for Blueprint Medicines. While the company's initial commercial success was rooted in oncology by targeting disease-driving mutations in KIT, the BLU-808 program targets the wild-type version of the same protein. This is not a redundant effort but a strategic application of core scientific competency to a different set of diseases with a distinct underlying biology. The central therapeutic hypothesis is that while mutant KIT drives the neoplastic proliferation of mast cells in SM, wild-type KIT signaling is the fundamental axis controlling the survival, differentiation, proliferation, and, most critically, the activation of mast cells in a wide array of common allergic and inflammatory diseases.[1] By potently and selectively inhibiting wild-type KIT, BLU-808 aims to modulate this core mast cell activity, thereby treating the root cause of these conditions rather than merely addressing downstream symptoms. This approach creates a "pipeline-in-a-product" opportunity, where a single, well-tolerated molecule could be developed across multiple large patient populations.

The initial target indications for BLU-808 underscore this broad potential, encompassing chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), allergic rhinoconjunctivitis, allergic asthma, and mast cell activation syndrome (MCAS).[2] This strategic pivot from rare oncology to broad-market immunology, built upon a foundation of world-class expertise in KIT biology, is a key factor that positioned Blueprint Medicines as a highly attractive acquisition target for Sanofi, a global leader in immunology.[4]

Attribute	Description	Source(s)
Drug Name	BLU-808	1
Alternative Names	BLU808, BLU 808	3
Developer	Blueprint Medicines (Acquired by Sanofi)	1
Drug Class	Small Molecule, Tyrosine Kinase Inhibitor	2
Mechanism of Action	Potent and selective oral inhibitor of wild-type KIT	1
Route of Administration	Oral	1
Target Indications	Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU), Allergic Rhinoconjunctivitis, Allergic Asthma, Mast Cell Activation Syndrome (MCAS)	2
Development Stage	Phase 2 (as of June 2025)	2

Scientific Rationale and Preclinical Evidence: Engineering for Potency and Selectivity

The development of BLU-808 is founded on a rational drug design strategy aimed at maximizing on-target potency while engineering out known liabilities of the tyrosine kinase inhibitor class. The resulting preclinical profile demonstrates a molecule with the potential for a wide therapeutic index, a critical attribute for therapies intended for chronic inflammatory conditions.

In Vitro Potency and Selectivity Profile

BLU-808 has shown exceptional potency against its intended target, wild-type KIT. In cellular assays, it inhibits KIT phosphorylation (pKIT) with a half-maximal inhibitory concentration (IC50​) of 0.37 nM and blocks KIT-dependent cell proliferation with an IC50​ of 1.3 nM.[7] This potent activity translates directly to mast cells, where BLU-808 inhibits degranulation of human CD34+ derived mast cells with an

IC50​ of 2.7 nM (as measured by CD63 surface expression) and 8.6 nM (as measured by histamine release).[7]

A defining feature of BLU-808 is its "best-in-class" selectivity profile.[5] This high degree of selectivity is not an incidental finding but rather the result of a deliberate drug design strategy to avoid the off-target activities that have historically plagued other KIT inhibitors and led to clinical toxicities. BLU-808 is highly selective against structurally related kinases that are known liabilities. Specifically, it is over 300-fold more selective for KIT than for platelet-derived growth factor receptor alpha (PDGFRA), over 400-fold more selective than for PDGFRB, and over 9,600-fold more selective than for FMS-like tyrosine kinase 3 (FLT3).[7] It also demonstrates over 800-fold selectivity against colony-stimulating factor 1 receptor (CSF1R).[7] This precision is confirmed by broad kinome screening, which yielded a high selectivity score (S(10) @ 3 μM) of 0.042, indicating minimal interaction with other kinases across the human kinome.[7]

Furthermore, BLU-808 was engineered to be peripherally restricted, with a low brain penetrance (Kp,uu​) of 0.021, which is intended to minimize the potential for central nervous system (CNS) side effects.[11] This combination of high on-target potency and exquisite selectivity forms the scientific basis for the wide therapeutic index and favorable safety profile observed in subsequent human studies.

In Vivo Preclinical Models

The potent and selective in vitro profile of BLU-808 has been validated in multiple in vivo preclinical models, demonstrating its ability to modulate mast cell activity and impact disease-relevant pathophysiology.

In studies designed to assess direct effects on mast cells, daily oral administration of BLU-808 in rats for seven days resulted in a dose-dependent reduction and depletion of mast cells in both skin and tongue tissues, confirming target engagement and biological effect in living systems.[5]

In a well-established rodent model of allergic asthma (ovalbumin-induced), a single oral dose of BLU-808 demonstrated significant therapeutic activity. It improved lung function by inhibiting airway hyper-responsiveness (measured by enhanced pause, or Penh) and acutely suppressed the infiltration of inflammatory immune cells into the bronchial alveolar lavage fluid (BALF).[5]

The potential of BLU-808 in urticaria was explored using an ex vivo model where human mast cells were challenged with serum from patients with chronic inducible urticaria (CIndU). In this system, BLU-808 completely inhibited mast cell degranulation, reducing activation to levels seen with serum from healthy donors. Notably, this effect was superior to that of the anti-IgE antibody omalizumab and the BTK inhibitor remibrutinib, which did not inhibit degranulation in this specific serum-induced model, highlighting the fundamental role of KIT in this process.[11]

Parameter	Metric/Finding	Source(s)
In Vitro Potency
pKIT Cellular IC50​	0.37 nM	7
WT KIT Proliferation IC50​	1.3 nM	7
CD63 Expression IC50​ (Mast Cells)	2.7 nM	7
Histamine Release IC50​ (Mast Cells)	8.6 nM	7
Kinase Selectivity
vs. PDGFRA	>300-fold	7
vs. PDGFRB	>400-fold	7
vs. FLT3	>9,600-fold	7
vs. CSF1R	>800-fold	7
In Vivo Activity
Mast Cell Modulation	Dose-dependent mast cell depletion in skin and tongue	5
Allergic Asthma Model	Improved lung function and reduced immune cell infiltration	7

Clinical Development and Human Pharmacodata

The robust preclinical profile of BLU-808 provided a strong foundation for its advancement into human clinical trials. The completed Phase 1 study in healthy volunteers has yielded exceptionally positive results, significantly de-risking the program and paving the way for a broad Phase 2 development plan across multiple mast cell-driven diseases.

Phase 1 Healthy Volunteer Study (NCT06948032)

The initial clinical evaluation of BLU-808 was conducted in a three-part, randomized, double-blind, placebo-controlled Phase 1 trial designed to assess its safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD).[2] The study included single-ascending dose (SAD) cohorts involving 56 participants and multiple-ascending dose (MAD) cohorts where 31 participants received 14 days of dosing.[8] The trial also incorporated assessments of the effect of food on absorption and the potential for drug-drug interactions via co-administration with midazolam, a known substrate of the CYP3A enzyme.[2]

Safety and Tolerability

The safety profile of BLU-808 was remarkably clean and well-tolerated across all tested dose levels, which ranged from 1 mg to 12 mg once daily in the MAD cohorts.[8] All treatment-emergent adverse events (AEs) reported in participants who received BLU-808 were mild (Grade 1).[8] Critically, there were no serious adverse events (SAEs), no discontinuations, and no requirements for dose modification due to AEs.[8] Furthermore, no significant changes in clinical laboratory measures were observed.[8] This exceptionally favorable safety profile in early human testing is a direct reflection of the molecule's high selectivity, which was intentionally engineered during preclinical development to avoid off-target kinase activities known to cause toxicities.

Pharmacokinetics (PK)

The pharmacokinetic data from the Phase 1 trial confirmed that BLU-808 is suitable for clinical development as a convenient oral therapy. The drug exhibited a half-life of approximately 40 hours, which strongly supports a once-daily (QD) dosing schedule.[8] Drug exposure increased in a consistent and dose-dependent manner. In the MAD cohorts, sustained target coverage was achieved across the dose range, with mean plasma concentrations exceeding the predicted KIT

IC50​ at doses of 1 mg QD and higher, and exceeding the predicted IC90​ at doses of 3 mg QD and higher.[8]

Pharmacodynamics (PD)

The study provided unambiguous evidence of target engagement in humans through the measurement of serum tryptase, a key enzyme released by mast cells and a validated biomarker of mast cell activity. BLU-808 demonstrated rapid, robust, and sustained dose-dependent reductions in serum tryptase levels.[8] In the MAD cohorts, the mean reduction in tryptase from baseline at Day 15 was profound, reaching -23% at 1 mg, -41% at 3 mg, -66% at 6 mg, and a remarkable -87% at the 12 mg dose.[8] At the higher dose levels, a substantial proportion of participants experienced tryptase reductions to levels below the lower limit of quantification (LLOQ), indicating near-complete suppression of this marker of mast cell activity.[8]

The ability to achieve such a strong pharmacodynamic effect at doses that were exceptionally well-tolerated establishes a very wide therapeutic window for BLU-808. This significantly de-risks the program's transition into Phase 2, as the primary clinical question shifts from one of safety and target engagement to quantifying the degree of clinical benefit that this potent mast cell modulation provides in specific patient populations.

Dose Cohort (MAD)	Placebo	1 mg	3 mg	6 mg	12 mg
Key Safety Finding	-	All AEs Grade 1; No SAEs; No discontinuations due to AEs	All AEs Grade 1; No SAEs; No discontinuations due to AEs	All AEs Grade 1; No SAEs; No discontinuations due to AEs	All AEs Grade 1; No SAEs; No discontinuations due to AEs
Key PK Finding	-	Half-life ~40 hours, supports QD dosing	Half-life ~40 hours, supports QD dosing	Half-life ~40 hours, supports QD dosing	Half-life ~40 hours, supports QD dosing
PD: Mean Tryptase Reduction (Day 15)	-4%	-23%	-41%	-66%	-87%
PD: Participants with Tryptase < LLOQ	0/8	1/6	1/6	3/6	3/4
Source(s): 2

Ongoing Phase 2 Clinical Program

Buoyed by the strong Phase 1 results, Blueprint Medicines has rapidly advanced BLU-808 into a broad proof-of-concept clinical program targeting several allergic and inflammatory diseases.

• NCT06931405: This is a global, two-part Phase 2 study designed to evaluate the safety, tolerability, and clinical activity of BLU-808 in patients with chronic urticaria. Part A is an open-label investigation in patients with Chronic Inducible Urticaria (CIndU), while Part B is a randomized, double-blind, placebo-controlled investigation in patients with Chronic Spontaneous Urticaria (CSU). The trial is enrolling patients whose condition is inadequately controlled by second-generation H1-antihistamines.[2]
• NCT06922448: This is a Phase 2a randomized, double-blind, placebo-controlled study designed to assess the safety, PK, PD, and preliminary clinical activity of BLU-808 in participants with ragweed-induced allergic rhinoconjunctivitis (ARC). Efficacy in this study will be evaluated in an allergen exposure chamber (AEC).[2]
• Future Studies: The company has also announced its strategy to initiate additional proof-of-concept studies for BLU-808 in allergic asthma and mast cell activation syndrome (MCAS) during the second half of 2025, further broadening the evaluation of this promising mast cell modulator.[9]

Trial ID	Indication(s)	Phase	Status	Primary Objective	Source(s)
NCT06931405	Chronic Spontaneous Urticaria (CSU) / Chronic Inducible Urticaria (CIndU)	2	Recruiting	Evaluate safety, tolerability, and clinical activity	2
NCT06922448	Allergic Rhinoconjunctivitis	2a	Recruiting	Evaluate safety, tolerability, and preliminary clinical activity	2
Planned	Allergic Asthma / Mast Cell Activation Syndrome (MCAS)	2	Planned (H2 2025)	Proof-of-concept	9

Competitive Landscape and Therapeutic Context

The development of BLU-808 occurs within a dynamic therapeutic landscape for mast cell-mediated diseases, particularly chronic urticaria. Its potential is best understood by contextualizing it against the limitations of current standards of care and the mechanisms of other emerging novel therapies.

Limitations of Current Chronic Urticaria Therapies

The current treatment paradigm for chronic urticaria is a stepwise approach that leaves a significant portion of patients with uncontrolled disease.

• First-Line Therapy: Second-generation H1-antihistamines are the initial standard of care. However, they provide inadequate symptom control for a majority of patients, with estimates suggesting that approximately 50-60% of individuals remain symptomatic even when the dose is increased up to fourfold.[23]
• Second-Line Therapy: For patients refractory to antihistamines, the injectable anti-IgE monoclonal antibody omalizumab (Xolair) is the recommended second-line agent. While effective for many, a substantial number of patients—at least 30%—have an insufficient response to this therapy.[24] Furthermore, omalizumab carries a black box warning for anaphylaxis, a serious safety concern.[28]
• Third-Line Therapy: The immunosuppressant cyclosporine is used off-label as a third-line option. Its utility is significantly limited by a challenging adverse effect profile, which includes risks of kidney dysfunction and hypertension, making it unsuitable for long-term use in many patients.[25]

Emerging Novel Therapeutic Mechanisms

The significant unmet need in chronic urticaria has spurred the development of several novel therapeutic approaches targeting different aspects of the disease pathophysiology.

• Next-Generation Anti-IgE (Ligelizumab): Developed by Novartis, ligelizumab is a monoclonal antibody designed to bind IgE with higher affinity than omalizumab. Despite initial promise, it failed to demonstrate superiority over omalizumab in pivotal Phase 3 trials for urticaria, and its development for this indication was subsequently terminated.[29] This outcome underscores the high bar for improving upon the established biologic standard of care.
• Bruton's Tyrosine Kinase (BTK) Inhibition (Remibrutinib): Also from Novartis, remibrutinib is an oral BTK inhibitor. BTK is a critical signaling enzyme downstream of the high-affinity IgE receptor (FcεRI) in mast cells. In the Phase 3 REMIX-1 and REMIX-2 trials, remibrutinib demonstrated rapid and significant efficacy in reducing symptoms in CSU patients who were refractory to antihistamines, establishing BTK inhibition as a viable oral therapeutic strategy.[33]
• KIT Inhibition (Barzolvolimab): Developed by Celldex, barzolvolimab is an injectable monoclonal antibody that, like BLU-808, targets the KIT receptor. Phase 2 data have shown profound, rapid, and durable responses in patients with both CSU and CIndU, including very high rates of complete response (defined as a Urticaria Activity Score of 0).[38]

Comparative Analysis: KIT Inhibition versus BTK Inhibition

A key strategic question for the future of oral therapies in mast cell diseases is the relative merit of targeting KIT versus BTK.

• Mechanistic Differentiation: KIT is the master regulator of mast cell biology, controlling the differentiation, survival, and activation of these cells.[5] BTK, while critical, is a signaling node primarily downstream of receptor-mediated activation, most notably the IgE receptor.[43] This distinction is crucial. By targeting KIT, an inhibitor like BLU-808 can theoretically control mast cell function irrespective of the specific upstream activation trigger. This could confer a significant advantage, as not all forms of chronic urticaria are believed to be IgE-driven.[25] A BTK inhibitor, while highly effective in IgE-mediated pathways, may be less effective in disease endotypes driven by other stimuli. Therefore, KIT inhibition represents a more fundamental and potentially more broadly applicable approach to mast cell modulation.
• Safety and Tolerability as a Differentiator: The history of kinase inhibitors is marked by challenges with off-target effects. First-generation BTK inhibitors, such as ibrutinib, are associated with significant off-target toxicities, including cardiovascular and bleeding risks.[47] While next-generation inhibitors like remibrutinib have been engineered for greater selectivity, the class as a whole carries a perception of risk that must be overcome. In this context, the exceptionally clean safety profile demonstrated by BLU-808 in its Phase 1 trial—where all AEs were only Grade 1—could emerge as a paramount competitive advantage, particularly for a therapy intended for chronic, non-malignant conditions.[8]

Drug	Company	Target/MOA	Modality	Development Stage	Key Efficacy Highlight	Key Safety Highlight	Source(s)
BLU-808	Blueprint/Sanofi	Wild-type KIT inhibitor	Oral Small Molecule	Phase 2	>80% tryptase reduction (Ph1)	Excellent tolerability (Grade 1 AEs only in Ph1)	2
Remibrutinib	Novartis	BTK inhibitor	Oral Small Molecule	Phase 3 (Filed)	Rapid UAS7 reduction (Ph3)	Generally well-tolerated	33
Barzolvolimab	Celldex	KIT inhibitor (mAb)	Injectable mAb	Phase 3	High complete response rate (Ph2)	Reversible KIT-related AEs	38
Omalizumab	Genentech/Novartis	Anti-IgE (mAb)	Injectable mAb	Approved	Established efficacy	Anaphylaxis warning	28

Strategic and Commercial Analysis: The Sanofi Acquisition

The trajectory and perceived value of BLU-808 were profoundly impacted by the June 2025 announcement of Sanofi's acquisition of Blueprint Medicines. This transaction provides not only the financial and operational resources of a global pharmaceutical leader but also serves as a powerful external validation of the asset's strategic importance and commercial potential.

Transaction Overview

Sanofi agreed to acquire Blueprint Medicines for an upfront cash payment of $129.00 per share, which translates to a total equity value of approximately $9.1 billion.[6] The stated strategic rationale for Sanofi was to enhance its pipeline and accelerate its transformation into a leading immunology company, with Blueprint's portfolio in SM and KIT-driven diseases being a cornerstone of the deal.[4]

The BLU-808 Contingent Value Right (CVR)

A pivotal and highly informative component of the acquisition agreement is the inclusion of a non-tradeable Contingent Value Right (CVR) specifically tied to the future success of BLU-808.[6] This CVR structure entitles Blueprint shareholders to receive up to two additional payments, contingent upon the achievement of pre-defined milestones for BLU-808:

• $2.00 per share: Payable upon the achievement of a specified clinical development milestone.
• $4.00 per share: Payable upon the achievement of a specified regulatory milestone.

These potential payments add approximately $400 million to the total potential value of the transaction, bringing it to roughly $9.5 billion.[6]

The inclusion of a CVR specifically focused on BLU-808 is a clear strategic signal. It indicates that while Sanofi placed significant value on Blueprint's commercial asset, AYVAKIT, a substantial portion of the acquisition premium is explicitly linked to the unrealized, future potential of BLU-808. This deal structure allows Sanofi to offer a higher total potential price, rewarding Blueprint shareholders for future success, while mitigating its own upfront financial risk. For this structure to be proposed, it is evident that Sanofi, after conducting extensive due diligence and reviewing the complete, non-public data package for BLU-808, has concluded that the asset possesses a high probability of success and blockbuster commercial potential.

This acquisition fundamentally de-risks the BLU-808 program from a development and commercialization standpoint. The asset is now in the hands of a global pharmaceutical leader with deep resources and a formidable presence in the immunology market. This greatly increases the likelihood that BLU-808 will be advanced efficiently through late-stage trials and, if successful, launched effectively on a global scale.

Parameter	Details	Source(s)
Acquirer	Sanofi	6
Target	Blueprint Medicines	6
Upfront Price per Share	$129.00	6
Total Equity Value (Upfront)	~$9.1 Billion	6
CVR Milestone 1 (Clinical)	$2.00 per share	6
CVR Milestone 2 (Regulatory)	$4.00 per share	6
Total Potential Deal Value	~$9.5 Billion	6

Concluding Analysis and Forward Outlook

BLU-808 has emerged as a highly promising, potential best-in-class oral therapy for a broad range of mast cell-mediated diseases. Its development program is underpinned by a confluence of strengths that position it favorably for future success.

The scientific rationale is compelling, targeting wild-type KIT, the master regulator of mast cell function. This fundamental mechanism offers the potential for broader efficacy across diverse disease endotypes compared to therapies targeting more downstream pathways. The drug's design reflects a sophisticated, modern approach to medicinal chemistry, successfully engineering exceptional potency while maintaining a best-in-class selectivity profile that avoids the known liabilities of earlier kinase inhibitors.

This meticulous preclinical design has been validated in human studies. The completed Phase 1 trial in healthy volunteers yielded an exceptionally clean safety profile, with no adverse events above Grade 1, and simultaneously demonstrated profound, dose-dependent target engagement. This establishment of a wide therapeutic window significantly de-risks the program as it advances into patient populations.

The strategic context for BLU-808 has been dramatically enhanced by the acquisition of Blueprint Medicines by Sanofi. This move not only provides the robust financial and operational infrastructure of a global pharmaceutical leader but also serves as a powerful external validation of the asset's potential, underscored by the specific inclusion of a milestone-based CVR for BLU-808 in the deal terms.

While the primary risk remains the successful translation of this promising profile into clinical efficacy in ongoing Phase 2 trials, the opportunity is substantial. BLU-808 represents a potential "pipeline-in-a-product," with the ability to expand from an initial indication in chronic urticaria into a multi-billion-dollar franchise covering allergic asthma, rhinoconjunctivitis, and other mast cell disorders.

In conclusion, BLU-808 is one of the most promising oral immunology assets currently in mid-stage clinical development. Its combination of a fundamental mechanism, best-in-class selectivity, pristine early clinical safety, and strong corporate backing positions it as a potential transformative therapy. The forthcoming data from the Phase 2 proof-of-concept studies in 2025 will be the next critical catalyst in determining its path toward becoming a cornerstone treatment for patients with mast cell-mediated diseases.

Works cited

1. Core programs | Blueprint Medicines, accessed June 20, 2025, [https://www.blueprintmedicines.com/pipeline/core\-programs/]
2. BLU-808 | Advanced Drug Monograph - MedPath, accessed June 20, 2025, [https://trial.medpath.com/drug/report/c81c5ad132d73762]
3. BLU-808 Drug Profile - Ozmosi, accessed June 20, 2025, [https://pryzm.ozmosi.com/product/30855]
4. BLU-808 - Drug Targets, Indications, Patents - Patsnap Synapse, accessed June 20, 2025, [https://synapse.patsnap.com/drug/3660a75715c64fb49a072421ed5e50e6]
5. Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Rese, accessed June 20, 2025, [https://www.blueprintmedicines.com/wp\-content/uploads/2024/02/Blueprint\-Medicines\-Press\-Release\-AAAAI\-2024\-February\-23\-2024\.pdf]
6. Press Release: Sanofi to acquire Blueprint Medicines, expanding ..., accessed June 20, 2025, [https://www.sanofi.com/en/media\-room/press\-releases/2025/2025\-06\-02\-05\-00\-00\-3091541]
7. BLU-808, a Potent and Selective Small Molecule Inhibitor of Wild ..., accessed June 20, 2025, [https://www.blueprintmedicines.com/wp\-content/uploads/2024/02/Blueprint\-Medicines\-AAAAI\-2024\-BLU\-808\-Wild\-Type\-KIT\-Mast\-Cell\-Disorders\-Poster.pdf]
8. Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth, accessed June 20, 2025, [https://firstwordpharma.com/story/5927061]
9. Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth, accessed June 20, 2025, [https://www.prnewswire.com/news\-releases/blueprint\-medicines\-provides\-2025\-outlook\-and\-highlights\-strategy\-for\-continued\-growth\-302348688\.html]
10. Blueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance, accessed June 20, 2025, [https://ir.blueprintmedicines.com/news\-releases/news\-release\-details/blueprint\-medicines\-reports\-first\-quarter\-2025\-results\-and]
11. BLU-808: A Potent and Selective Oral Small Molecule Wild-Type KIT ..., accessed June 20, 2025, [https://www.blueprintmedicines.com/wp\-content/uploads/2025/02/Blueprint\-Medicines\-AAAAI\-WAO\-2025\-BLU\-808\-Wild\-Type\-KIT\-Inhibitor\-Poster.pdf]
12. Study of BLU-808 in Healthy Adult Participants - ClinicalTrials.Veeva, accessed June 20, 2025, [https://ctv.veeva.com/study/study\-of\-blu\-808\-in\-healthy\-adult\-participants]
13. Blueprint Medicines Announces Positive BLU-808 Phase 1 Data and 2025 Growth Strategy, accessed June 20, 2025, [https://trial.medpath.com/news/cee8c44ecb4ce91a/blueprint\-medicines\-provides\-2025\-outlook\-and\-highlights\-strategy\-for\-continued\-growth]
14. Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint Congress, accessed June 20, 2025, [https://ir.blueprintmedicines.com/news\-releases/news\-release\-details/blueprint\-medicines\-highlights\-leading\-portfolio\-mast\-cell]
15. Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint Congress - PR Newswire, accessed June 20, 2025, [https://www.prnewswire.com/news\-releases/blueprint\-medicines\-highlights\-leading\-portfolio\-of\-mast\-cell\-targeted\-therapies\-at\-2025\-aaaai\-\-wao\-joint\-congress\-302388179\.html]
16. Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint Congress - Stock Titan, accessed June 20, 2025, [https://www.stocktitan.net/news/BPMC/blueprint\-medicines\-highlights\-leading\-portfolio\-of\-mast\-cell\-6vf3mki1zlzb.html]
17. Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and ..., accessed June 20, 2025, [https://ctv.veeva.com/study/study\-of\-blu\-808\-in\-chronic\-inducible\-urticaria\-cindu\-and\-chronic\-spontaneous\-urticaria\-csu]
18. Blueprint Medicines Corp. - Drug pipelines, Patents, Clinical trials - Patsnap Synapse, accessed June 20, 2025, [https://synapse.patsnap.com/organization/db9db3870e6e5b1b76329a90eeb24fa5]
19. Allergic rhinoconjunctivitis - Drugs, Targets, Patents - Patsnap Synapse, accessed June 20, 2025, [https://synapse.patsnap.com/disease/d22742f2a16941c8815673da33af4064]
20. Study of BLU-808 in Allergic Rhinoconjunctivitis - ClinicalTrials.Veeva, accessed June 20, 2025, [https://ctv.veeva.com/study/study\-of\-blu\-808\-in\-allergic\-rhinoconjunctivitis]
21. Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth, accessed June 20, 2025, [https://ir.blueprintmedicines.com/news\-releases/news\-release\-details/blueprint\-medicines\-provides\-2025\-outlook\-and\-highlights]
22. Blueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance - FirstWord Pharma, accessed June 20, 2025, [https://firstwordpharma.com/story/5956041]
23. Full article: An update on the use of antihistamines in managing chronic urticaria, accessed June 20, 2025, [https://www.tandfonline.com/doi/full/10\.1080/14656566\.2024\.2345731]
24. Chronic Urticaria: Addressing unmet needs, emerging therapies, and advances in personalized treatment approaches - News-Medical.net, accessed June 20, 2025, [https://www.news\-medical.net/news/20240716/Chronic\-Urticaria\-Addressing\-unmet\-needs\-emerging\-therapies\-and\-advances\-in\-personalized\-treatment\-approaches.aspx]
25. Current and Emerging Therapies for Chronic Spontaneous Urticaria: A Narrative Review, accessed June 20, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10366054/]
26. Chronic Spontaneous Urticaria A Review - BINASSS, accessed June 20, 2025, [https://www.binasss.sa.cr/nov24/34\.pdf]
27. Therapies for Chronic Spontaneous Urticaria: Present and Future Developments - MDPI, accessed June 20, 2025, [https://www.mdpi.com/1424\-8247/17/11/1499]
28. Chronic Spontaneous Urticaria (CSU) Treatment Clinical Trial Results | XOLAIR® (omalizumab) | HCP, accessed June 20, 2025, [https://www.xolairhcp.com/chronic\-spontaneous\-urticaria/efficacy/clinical\-trial\-results.html]
29. Ligelizumab - Wikipedia, accessed June 20, 2025, [https://en.wikipedia.org/wiki/Ligelizumab]
30. Ligelizumab for Chronic Hives: How It Works and Side Effects - Verywell Health, accessed June 20, 2025, [https://www.verywellhealth.com/ligelizumab\-6455834]
31. US breakthrough designation for ligelizumab in chronic spontaneous urticaria, accessed June 20, 2025, [https://pharmatimes.com/news/us\_breakthrough\_designation\_for\_ligelizumab\_in\_chronic\_spontaneous\_urticaria\_1361362/]
32. Novartis ligelizumab (QGE031) receives FDA Breakthrough Therapy designation for patients with chronic spontaneous urticaria (CSU), accessed June 20, 2025, [https://www.novartis.com/news/media\-releases/novartis\-ligelizumab\-qge031\-receives\-fda\-breakthrough\-therapy\-designation\-patients\-chronic\-spontaneous\-urticaria\-csu]
33. Remibrutinib alleviates symptoms in chronic spontaneous urticaria resistant to H1-antihistamines | 2 Minute Medicine, accessed June 20, 2025, [https://www.2minutemedicine.com/remibrutinib\-alleviates\-symptoms\-in\-chronic\-spontaneous\-urticaria\-resistant\-to\-h1\-antihistamines/]
34. Phase III Trials Confirm Remibrutinib Effectively Reduces Chronic Spontaneous Urticaria Symptoms, accessed June 20, 2025, [https://www.appliedclinicaltrialsonline.com/view/remibrutinib\-chronic\-spontaneous\-urticaria\-symptoms]
35. Remibrutinib in Chronic Spontaneous Urticaria - PubMed, accessed June 20, 2025, [https://pubmed.ncbi.nlm.nih.gov/40043237/]
36. Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks - PubMed, accessed June 20, 2025, [https://pubmed.ncbi.nlm.nih.gov/37866460/]
37. Remibrutinib for chronic spontaneous urticaria: Phase 2b extension study results, accessed June 20, 2025, [https://www.aaaai.org/tools\-for\-the\-public/latest\-research\-summaries/the\-journal\-of\-allergy\-and\-clinical\-immunology/2023\-the\-journal\-of\-allergy\-and\-clinical\-immunolog/remibrutinib]
38. Barzolvolimab Demonstrates Rapid Symptom Reduction in Chronic Spontaneous Urticaria, accessed June 20, 2025, [https://www.dermatologytimes.com/view/barzolvolimab\-demonstrates\-rapid\-symptom\-reduction\-in\-chronic\-spontaneous\-urticaria]
39. Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025, accessed June 20, 2025, [https://ir.celldex.com/news\-releases/news\-release\-details/celldex\-presents\-unprecedented\-76\-week\-results\-barzolvolimab]
40. Barzolvolimab (CDX-0159) | Anti-KIT Antibody - MedchemExpress.com, accessed June 20, 2025, [https://www.medchemexpress.com/barzolvolimab.html]
41. Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025, accessed June 20, 2025, [https://ir.celldex.com/news\-releases/news\-release\-details/celldex\-presents\-data\-demonstrating\-profound\-long\-term]
42. Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025, accessed June 20, 2025, [https://ir.celldex.com/news\-releases/news\-release\-details/celldex\-therapeutics\-presents\-positive\-results\-barzolvolimab]
43. BTK Assay Kit - BPS Bioscience, accessed June 20, 2025, [https://bpsbioscience.com/btk\-assay\-kit\-79568]
44. Bruton's Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis - PubMed Central, accessed June 20, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC9604914/]
45. Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models - PMC - PubMed Central, accessed June 20, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC6500888/]
46. The tyrosine kinase network regulating mast cell activation - PMC - PubMed Central, accessed June 20, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC2669301/]
47. Comprehensive Characterization of Bruton's Tyrosine Kinase Inhibitor Specificity, Potency, and Biological Effects: Insights into Covalent and Noncovalent Mechanistic Signatures - ACS Publications, accessed June 20, 2025, [https://pubs.acs.org/doi/10\.1021/acsptsci.4c00540]
48. Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets – Beyond B Lymphocytes - Frontiers, accessed June 20, 2025, [https://www.frontiersin.org/journals/cell\-and\-developmental\-biology/articles/10\.3389/fcell.2021\.727531/full]